Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures
- PMID: 12124311
- DOI: 10.1124/dmd.30.8.924
Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures
Abstract
The effect of discrete esters and ester mixtures on the intestinal stability and absorption of tenofovir disoproxil fumarate (tenofovir DF, an esterase-sensitive prodrug of the antiviral tenofovir) was compared with the effect of strawberry extract, which has been shown to enhance the absorption of the prodrug across Caco-2 monolayers and in rat ileum. In addition, the mechanism of absorption enhancement was investigated. In rat intestinal homogenates, complete inhibition of the conversion of tenofovir DF (as obtained by strawberry extract) could only be obtained at relatively high concentrations of the discrete esters or by using mixtures of esters (e.g., propyl p-hydroxybenzoate 0.02%, octyl acetate 0.02%, ethyl caprylate 0.01%). Coincubation of tenofovir DF with this mixture also resulted in an enhancement of its absorption in the in vitro Caco-2 system as well as in rat ileum. As tenofovir DF is a substrate for P-glycoprotein (P-gp)-related efflux carriers in the Caco-2 model, the modulatory effect of the ester mixtures was studied on the functionality of P-gp using cyclosporin A (CsA) as a model substrate. Strawberry extract as well as the mixture of three esters interfered with the absorptive transport of CsA across Caco-2 monolayers, illustrating that both mixtures interfere with both esterase-activity and P-gp functionality. This concerted barrier was not observed in rat ileum, suggesting differential functional activities of the biochemical barrier toward tenofovir DF in different absorption systems. Overall, our results illustrate that modulation of the biochemical barrier (metabolism and efflux) of tenofovir DF by ester mixtures can be used to increase the intestinal absorption of tenofovir DF in an in vitro and an in situ absorption model; the mechanism of action appears to be a complex interplay of different systems; the differential expression of carriers and enzymes in different systems illustrates the difficulty of extrapolating observations between different systems/species.
Similar articles
-
Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.Clin Pharmacokinet. 2004;43(9):595-612. doi: 10.2165/00003088-200443090-00003. Clin Pharmacokinet. 2004. PMID: 15217303 Review.
-
Inhibition of intestinal metabolism of the antiviral ester prodrug bis(POC)-PMPA by nature-identical fruit extracts as a strategy to enhance its oral absorption: an in vitro study.Pharm Res. 1999 Jul;16(7):1035-40. doi: 10.1023/a:1018931631912. Pharm Res. 1999. PMID: 10450927
-
Increased absorption of the antiviral ester prodrug tenofovir disoproxil in rat ileum by inhibiting its intestinal metabolism.Drug Metab Dispos. 2000 Dec;28(12):1394-6. Drug Metab Dispos. 2000. PMID: 11095573
-
Species-dependent and site-specific intestinal metabolism of ester prodrugs.Int J Pharm. 2000 Sep 15;205(1-2):93-100. doi: 10.1016/s0378-5173(00)00507-x. Int J Pharm. 2000. PMID: 11000545
-
Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.Clin Ther. 2002 Oct;24(10):1515-48. doi: 10.1016/s0149-2918(02)80058-3. Clin Ther. 2002. PMID: 12462284 Review.
Cited by
-
A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.Biomaterials. 2013 Aug;34(26):6202-28. doi: 10.1016/j.biomaterials.2013.05.012. Epub 2013 May 28. Biomaterials. 2013. PMID: 23726227 Free PMC article. Review.
-
Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.Antimicrob Agents Chemother. 2004 Jun;48(6):2091-6. doi: 10.1128/AAC.48.6.2091-2096.2004. Antimicrob Agents Chemother. 2004. PMID: 15155205 Free PMC article. Clinical Trial.
-
Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate.PLoS One. 2019 Dec 11;14(12):e0226276. doi: 10.1371/journal.pone.0226276. eCollection 2019. PLoS One. 2019. PMID: 31826005 Free PMC article. Clinical Trial.
-
Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.Clin Pharmacokinet. 2004;43(9):595-612. doi: 10.2165/00003088-200443090-00003. Clin Pharmacokinet. 2004. PMID: 15217303 Review.
-
Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy.J Clin Pharmacol. 2007 Aug;47(8):970-7. doi: 10.1177/0091270007302564. Epub 2007 Jul 5. J Clin Pharmacol. 2007. PMID: 17615254 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous